169 related articles for article (PubMed ID: 3519883)
1. Ten-year results from the National Surgical Adjuvant Breast and Bowel Project (NSABP) clinical trial evaluating the use of L-phenylalanine mustard (L-PAM) in the management of primary breast cancer.
Fisher B; Fisher ER; Redmond C
J Clin Oncol; 1986 Jun; 4(6):929-41. PubMed ID: 3519883
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the National Surgical Adjuvant Breast and Bowel Project Trial.
Fisher B; Redmond C; Brown A; Fisher ER; Wolmark N; Bowman D; Plotkin D; Wolter J; Bornstein R; Legault-Poisson S
J Clin Oncol; 1986 Apr; 4(4):459-71. PubMed ID: 2856857
[TBL] [Abstract][Full Text] [Related]
3. 1-phenylalanine mustard (L-PAM) in the management of premenopausal patients with primary breast cancer: lack of association of disease-free survival with depression of ovarian function. National Surgical Adjuvant Project for Breast and Bowel Cancers.
Fisher B; Sherman B; Rockette H; Redmond C; Margolese R; Fisher ER
Cancer; 1979 Sep; 44(3):847-57. PubMed ID: 383274
[TBL] [Abstract][Full Text] [Related]
4. Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer.
Fisher B; Jeong JH; Dignam J; Anderson S; Mamounas E; Wickerham DL; Wolmark N
J Natl Cancer Inst Monogr; 2001; (30):62-6. PubMed ID: 11773294
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study.
Rivkin SE; Green SJ; Lew D; Costanzi JJ; Athens JW; Osborne CK; Vaughn CB; Martino S
Cancer; 2003 Jan; 97(1):21-9. PubMed ID: 12491501
[TBL] [Abstract][Full Text] [Related]
6. Systemic adjuvant therapy in treatment of primary operable breast cancer: National Surgical Adjuvant Breast and Bowel Project experience.
Fisher B; Redmond C; Fisher ER; Wolmark N
NCI Monogr; 1986; (1):35-43. PubMed ID: 3534589
[TBL] [Abstract][Full Text] [Related]
7. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil.
Fisher B; Dignam J; Mamounas EP; Costantino JP; Wickerham DL; Redmond C; Wolmark N; Dimitrov NV; Bowman DM; Glass AG; Atkins JN; Abramson N; Sutherland CM; Aron BS; Margolese RG
J Clin Oncol; 1996 Jul; 14(7):1982-92. PubMed ID: 8683228
[TBL] [Abstract][Full Text] [Related]
8. Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer.
Fisher B; Redmond C; Brown A; Wickerham DL; Wolmark N; Allegra J; Escher G; Lippman M; Savlov E; Wittliff J
J Clin Oncol; 1983 Apr; 1(4):227-41. PubMed ID: 6366135
[TBL] [Abstract][Full Text] [Related]
9. Leukemia in breast cancer patients following adjuvant chemotherapy or postoperative radiation: the NSABP experience.
Fisher B; Rockette H; Fisher ER; Wickerham DL; Redmond C; Brown A
J Clin Oncol; 1985 Dec; 3(12):1640-58. PubMed ID: 3906049
[TBL] [Abstract][Full Text] [Related]
10. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16.
Fisher B; Redmond C; Legault-Poisson S; Dimitrov NV; Brown AM; Wickerham DL; Wolmark N; Margolese RG; Bowman D; Glass AG
J Clin Oncol; 1990 Jun; 8(6):1005-18. PubMed ID: 2189950
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant CMFVP versus melphalan for operable breast cancer with positive axillary nodes: 10-year results of a Southwest Oncology Group Study.
Rivkin SE; Green S; Metch B; Glucksberg H; Gad-el-Mawla N; Constanzi JJ; Hoogstraten B; Athens J; Maloney T; Osborne CK
J Clin Oncol; 1989 Sep; 7(9):1229-38. PubMed ID: 2671283
[TBL] [Abstract][Full Text] [Related]
12. Disease-free survival at intervals during and following completion of adjuvant chemotherapy: the NSABP experience from three breast cancer protocols.
Fisher B; Redmond C; Wolmark N; Wieand HS
Cancer; 1981 Sep; 48(6):1273-80. PubMed ID: 7023651
[TBL] [Abstract][Full Text] [Related]
13. Doxorubicin-containing regimens for the treatment of stage II breast cancer: The National Surgical Adjuvant Breast and Bowel Project experience.
Fisher B; Redmond C; Wickerham DL; Bowman D; Schipper H; Wolmark N; Sass R; Fisher ER; Jochimsen P; Legault-Poisson S
J Clin Oncol; 1989 May; 7(5):572-82. PubMed ID: 2651576
[TBL] [Abstract][Full Text] [Related]
14. Ten year follow-up results of patients with carcinoma of the breast in a co-operative clinical trial evaluating surgical adjuvant chemotherapy.
Fisher B; Slack N; Katrych D; Wolmark N
Surg Gynecol Obstet; 1975 Apr; 140(4):528-34. PubMed ID: 805475
[TBL] [Abstract][Full Text] [Related]
15. Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18.
Fisher ER; Wang J; Bryant J; Fisher B; Mamounas E; Wolmark N
Cancer; 2002 Aug; 95(4):681-95. PubMed ID: 12209710
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant chemotherapy in stage-II breast cancer: an overview of the NSABP clinical trials.
Wolmark N; Fisher B
Breast Cancer Res Treat; 1983; 3 Suppl():S19-26. PubMed ID: 6367856
[TBL] [Abstract][Full Text] [Related]
17. Combination chemotherapy (CMFVP) versus L-phenylalanine mustard (L-PAM) for operable breast cancer with positive axillary nodes: a Southwest Oncology Group Study.
Glucksberg H; Rivkin SE; Rasmussen S; Tranum B; Gad-el-Mawla N; Costanzi J; Hoogstraten B; Athens J; Maloney T; McCracken J; Vaughn C
Cancer; 1982 Aug; 50(3):423-34. PubMed ID: 7046900
[TBL] [Abstract][Full Text] [Related]
18. Prognostic and therapeutic significance of pathological features of breast cancer.
Fisher ER
NCI Monogr; 1986; (1):29-34. PubMed ID: 3774014
[TBL] [Abstract][Full Text] [Related]
19. Systemic therapy in node-negative patients: updated findings from NSABP clinical trials. National Surgical Adjuvant Breast and Bowel Project.
Fisher B; Redmond C
J Natl Cancer Inst Monogr; 1992; (11):105-16. PubMed ID: 1627417
[TBL] [Abstract][Full Text] [Related]
20. Acute toxicity during adjuvant chemotherapy for breast cancer: the National Surgical Adjuvant Breast and Bowel Project (NSABP) experience from 1717 patients receiving single and multiple agents.
Glass A; Wieand HS; Fisher B; Redmond C; Lerner H; Wolter J; Shibata H; Plotkin D; Foster R; Margolese R; Wolmark N
Cancer Treat Rep; 1981; 65(5-6):363-76. PubMed ID: 7016322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
